Tirzepatide Cost: Mounjaro, Zepbound and Compounded Prices

Tirzepatide cost comes in three levels on the approximate figures used across GLPKit: Mounjaro at about $1,080 a month, Zepbound at about $1,060 a month, and compounded tirzepatide advertised from about $379 a month. The two branded figures are close because the products share an ingredient and a manufacturer. The compounded figure is lower because the product is different, and it is not FDA approved. This page explains all three.

One ingredient, two branded pens, close prices

Tirzepatide is sold under two brand names. Mounjaro is approved for type 2 diabetes, and Zepbound is approved for weight management and also for moderate to severe obstructive sleep apnea in adults with obesity. Both are once weekly injections with the same schedule shape: a 2.5 mg start, increases of 2.5 mg every at least 4 weeks, a maximum of 15 mg for Mounjaro, and maintenance doses of 5, 10 or 15 mg for Zepbound. In the SURMOUNT-1 trial, tirzepatide produced an average loss of 20.9 percent of body weight at the 15 mg dose at 72 weeks, a figure from the weight management research that sits behind the Zepbound side of the family.

Their approximate list prices sit close together, Mounjaro at about $1,080 a month and Zepbound at about $1,060 a month, a gap small enough that it should never drive the choice between them. The approval should. Coverage follows the diagnosis and the brand's approved use, so a person with type 2 diabetes and a person seeking weight management treatment can face completely different out of pocket results from two pens with nearly identical list prices. Your prescriber and your plan, between them, decide which side of that line your treatment sits on.

Mounjaro at about $1,080 a month

For Mounjaro, the about $1,080 monthly list figure is the benchmark before diabetes coverage is applied. Commercially insured patients with type 2 diabetes may pay far less after formulary placement, prior authorization and cost sharing, and manufacturer savings programs may apply under their terms for eligible commercially insured patients. Our dedicated Mounjaro cost page follows those factors one by one, including how pharmacy choice and dose stage affect the applied total you are quoted at the counter.

Because diabetes treatment is ongoing, think in longer periods. A year at list benchmark is a large number, and even a well covered copay repeats every month for as long as treatment continues. Budgeting honestly for that pattern, and rechecking it when your plan year resets or a program term changes, prevents the most common surprise in this whole category, which is a treatment that was affordable in month one becoming a problem in month seven because a deductible reset or a card expired.

Zepbound at about $1,060 a month

Zepbound's approximate list price of about $1,060 a month comes with a different coverage reality. Weight management coverage varies widely: some plans cover it with prior authorization criteria, some exclude it, and government programs have their own restrictions, so a larger share of Zepbound patients meet the list benchmark, a cash quote or a manufacturer program than is typical on the diabetes side. The sleep apnea approval gives some patients an additional covered use to discuss with their prescriber, judged on its own medical criteria.

Pharmacy cash quotes for Zepbound vary, as they do for every pen on this site, and presentation can matter to the quote you receive. The GLP-1 cost calculator runs the about $1,060 figure over the months you choose, which is the clearest way to compare it with the Mounjaro figure above or with the compounded figure below. Whichever route you take, the dose schedule is prescriber led, from the 2.5 mg start to a maintenance dose of 5, 10 or 15 mg, and the schedule should never be compressed to save money by using fewer pens than prescribed.

Compounded tirzepatide at about $379, labeled approximate

Compounded tirzepatide is typically advertised from about $379 a month. Keep both labels attached to that number: it is approximate, and the product is not FDA approved. Compounded versions are prepared by compounding pharmacies for individual prescriptions, usually as vials rather than fixed dose pens, without FDA review of the finished product for safety, effectiveness or manufacturing quality. Advertised figures are starting prices that commonly rise with dose, and telehealth services often add consultation or membership fees, so the real comparison is your total at your dose over your expected treatment period.

Our compounded tirzepatide cost guide goes deeper on advertised pricing and cautions, and the compounded savings calculator places the compounded figure beside a branded one over the same months. The FDA has warned about dosing errors in this market, which is a particular risk when a dose must be measured from a vial. If you and your prescriber consider this route, the pharmacy should be named, licensed and willing to answer questions, and the compounded nature of the product should be disclosed before payment, never discovered after it.

What changes what you actually pay

Across all three levels, the same four factors dominate. Diagnosis and approval come first, because they decide which brand and which coverage rules apply to you. Coverage mechanics come second: formulary position, prior authorization, deductible stage and cost sharing, plus savings card rules that generally require commercial insurance. Pharmacy comes third, because cash quotes and network pricing vary for identical prescriptions. Fees come fourth on telehealth and compounded routes, where consultation and membership charges sit outside the medicine figure entirely and can quietly narrow the gap the headline price promised.

The factor that should never appear on the list is a seller offering tirzepatide with no prescription, as a research chemical, or through social media messages. Those sources sit outside the licensed clinician and pharmacy system altogether, with no assurance the product is tirzepatide, sterile, or the strength claimed. If a legitimate route is unaffordable, the safe levers are the ones above: a different pharmacy, a program application, a coverage appeal, or a prescriber conversation about alternatives. They are slower than a gray market checkout, and they are the reason the medicine you receive is the medicine on the label.

Frequently asked questions

Back to all GLPKit guides